Glooko Highlights Hospital Glucose Management Offering at SHM Converge

According to a recent LinkedIn post from Glooko, the company’s team plans to participate in the Society of Hospital Medicine Converge Conference from March 29 to April 1. The post highlights a focus on the EndoTool Glucose Management System, developed by Monarch Medical Technologies, which Glooko identifies as a Glooko company.

The LinkedIn post suggests that EndoTool is positioned as a tool to help hospitals shift from reactive, uniform insulin protocols toward more proactive, data‑driven glycemic management. The content also links this approach to meeting newly required Centers for Medicare & Medicaid Services, or CMS, reporting guidelines.

For investors, the emphasis on CMS reporting alignment may indicate that Glooko is targeting regulatory‑driven demand in inpatient diabetes and glucose management. If hospitals adopt such systems to comply with evolving reporting standards, this could support recurring software or services revenue and strengthen Glooko’s foothold in the hospital segment.

The focus on Monarch Medical Technologies under the Glooko umbrella further underscores integration of acquired or affiliated technologies into Glooko’s broader portfolio. Greater visibility at a major hospital medicine conference may help the company build relationships with hospital decision‑makers, potentially influencing future contract wins and enhancing its competitive position in hospital glycemic safety solutions.